Since the deletion of Tet2 and Tet3 using Cd19Cre resulted in aggressive B cell lymphoma at an early age (unpublished observation), we used a tamoxifen-inducible Tet2/3-deletion system to circumvent this caveat as previously described (Lio et al., 2019). The gene discussed is TET3; the disease is B-cell non-Hodgkin lymphoma.